Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

319 ARTÍCULOS , VIENDO DEL 61 AL 75

Simpson's Paradox, Amyloid Paradox, and Racial Differences

Xiong C, Luo J, Lu R, Hartz S, Kukull W, Schindler SE, Balls-Berry JE, Hassenstab J, Wolk DA, Gleason CE, Johnson SC, Sperling R, Johnson K, Roberson ED, Moulder KL, Gremminger E, Agboola F, Grant EA, Hornbeck R, Massoumzadeh P, Keefe S, Dierker D, Flores S, Holtzman DM, Benzinger T, Morris JC.

JAMA Netw Open. 2026 Oct 1;9(10):e2640868. doi: 10.1001/jamanetworkopen.2026.40868.

Short-interval variability and test-retest reliability of Alzheimer's disease plasma biomarkers in a clinically heterogenous cohort

Beament M, Wiltshire K, Belder CRS, Abel E, Hart M, Heslegrave AJ, Lunn MP, Rosa-Grilo M, Swann O, Schott JM, Zetterberg H, Fox NC, Keshavan A.

Alzheimers Res Ther. 2026 Oct 27;18(1):238. doi: 10.1186/s13195-026-02180-8.

Blood-Based Biomarkers in Alzheimer's Disease: Advances in Detection Technologies and Clinical Applications

Li S, Huang L, Guo Q.

Aging Med (Milton). 2026 Oct 27:10.1002/agm2.70112. doi: 10.1002/agm2.70112. Online ahead of print.

Selective neuronal vulnerability in Alzheimer's disease: Mechanisms, biomarkers, and therapeutic implications

Tian-Yang X, Er-Deng E, Ting Z, Xiao-Qin Z.

Ageing Res Rev. 2026 Oct 29;123:103430. doi: 10.1016/j.arr.2026.103430. Online ahead of print.

A prospective observational study measuring the stability of plasma pTau181 using the Elecsys Phospho-Tau (181P) plasma immunoassay for early detection of Alzheimer's disease

Kurz C, Leonhardt S, Hufnagel A, Wizemann S, Deutelmoser H, Menzel P, Perneczky R.

Alzheimers Res Ther. 2026 Oct 24;18(1):240. doi: 10.1186/s13195-026-02238-7.

Can the integration of blood-based biomarkers into Alzheimer's disease diagnosis revolutionize the field?

Gaetani L, Nardi G, Parnetti L.

Expert Rev Neurother. 2026 Sep;26(9):839-852. doi: 10.1080/14737175.2026.2700246. Epub 2026 Jul 7.

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial

Croese T, Mummery CJ, Bregman N, Bracha D, Baruch K, Kertser A, Raveh S, Shochat E, Schwartz M.

Nat Med. 2026 Sep;32(9):3458-3465. doi: 10.1038/s41591-026-04547-8. Epub 2026 Jul 15.

Do sigma-1 receptor agonists offer therapeutic promise for Alzheimer's disease?

Panza F, Dibello V, Daniele A, Lozupone M.

Expert Opin Pharmacother. 2026 Aug;27(12):1243-1250. doi: 10.1080/14656566.2026.2706070. Epub 2026 Jul 20.

Acitretin-inspired medicinal chemistry for Alzheimer's disease: A biomarker-gated central nervous system (CNS) discovery framework

Qin TG, Han Y.

Drug Discov Ther. 2026 Sep 21;20(4):349-353. doi: 10.5582/ddt.2026.01054. Epub 2026 Aug 18.

Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease

Dineshbhai TK, Rafaliya D, Singh A, Maheshwari S, Lalan M, Chakraborthy GS.

Inflammopharmacology. 2026 Sep;34(9):6003-6034. doi: 10.1007/s10787-026-02341-z. Epub 2026 Aug 22.

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker

Paranhos T, Katsumi Y, Brickhouse MJ, Eloyan A, Eckbo R, Zaitsev A, Du A, La Joie R, Thangarajah M, Taurone A, Vemuri P, Jack CR; as the LEADS Consortium; Hammers DB, Aisen PS, Beckett LA, Koeppe R, Kukull WA, Toga AW, Atri A, Clark DG, Day GS, Duara R, Graff-Radford NR, Grant IM, Honig LS, Johnson E, Jones DT, Masdeu JC, Mendez MF, Musiek ES, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo T, Wolk DA, Womack KB, Carrillo MC, Rabinovici GD, Apostolova LG, Dickerson BC, Eldaief MC, Touroutoglou A.

Neurology. 2026 Oct 13;107(7):e218519. doi: 10.1212/WNL.0000000000218519. Epub 2026 Aug 26.

Rethinking tau-targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

Teunissen CE, Pini L, Imbimbo BP.

Alzheimers Dement. 2026 Sep;22(9):e71867. doi: 10.1002/alz.71867.

Overview in Electrochemical and Electrical Biosensors for Determining Blood Protein Biomarkers of Alzheimer's Disease

Gao F, Liu L, Li J, Chen S, Yi X.

Biosensors (Basel). 2026 Aug 6;16(8):426. doi: 10.3390/bios16080426.

Neuropsychiatric symptoms as early clinical indicators and functional biomarkers of cognitive decline in mild cognitive impairment and early Alzheimer's disease

de Levante Raphael D.

J Alzheimers Dis. 2026 Sep;113(1):5-15. doi: 10.1177/13872877261469114. Epub 2026 Jul 27.

Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort

Lv X, Shen K, Zhao Q, Peng G, Liu H, Gao F, Pan X, Chen W, Lu P, Zhang H, Zhang S, Xing M, Chen Q, Wang Y, Cheng Z, Wang Y, Zeng S, Xie F, Pan Y, Shen Y, Chen X, Shi J.

Sci Bull (Beijing). 2026 Sep 15;71(17):4506-4515. doi: 10.1016/j.scib.2026.08.018. Epub 2026 Aug 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias